Immunophenotypic characteristics of early T-cell precursor acute lymphoblastic leukemia

Шарлай, А. С.; Illarionova, Olga; Федюкова, Ю. Г.; Вержбицкая, Т. Ю.; Fechina, Larisa; Бойченко, Э. Г.; Карачунский, А. И.; Popov, Alexander

doi:10.24287/1726-1708-2019-18-2-66-74

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is mainly linked to the potential of leukemic cells for differentiation in both myeloid and T-lymphoid lineages. Such immaturity also results in similarities in the biological features of ETP-ALL and the T/Myelo type of MPAL [ 4 , 17 , 18 ]. In addition, the great lineage plasticity of early T-lineage leukemic blasts allows them to escape lymphoid-directed chemotherapy by the early switch to AML, which was demonstrated previously [ 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunophenotypic but Not Genetic Changes Reclassify the Majority of Relapsed/Refractory Pediatric Cases of Early T-Cell Precursor Acute Lymphoblastic Leukemia

Demina,

Dagestani,

Borkovskaia

et al. 2024

IJMS

View full text Add to dashboard Cite

Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) develops from very early cells with the potential for both T-cell and myeloid differentiation. The ambiguous nature of leukemic blasts in ETP-ALL may lead to immunophenotypic alterations at relapse. Here, we address immunophenotypic alterations and related classification issues, as well as genetic features of relapsed pediatric ETP-ALL. Between 2017 and 2022, 7518 patients were diagnosed with acute leukemia (AL). In addition to conventional immunophenotyping, karyotyping, and FISH studies, we performed next-generation sequencing of the T-cell receptor clonal repertoire and reverse transcription PCR and RNA sequencing for patients with ETP-ALL at both initial diagnosis and relapse. Among a total of 534 patients diagnosed with T-cell ALL (7.1%), 60 had ETP-ALL (11.2%). Ten patients with ETP-ALL experienced relapse or progression on therapy (16.7%), with a median time to event of 5 months (ranging from two weeks to 5 years). Most relapses were classified as AL of ambiguous lineage (n = 5) and acute myeloid leukemia (AML) (n = 4). Major genetic markers of leukemic cells remained unchanged at relapse. Of the patients with relapse, four had polyclonal leukemic populations and a relapse with AML or bilineal mixed-phenotype AL (MPAL). Three patients had clonal TRD rearrangements and relapse with AML, undifferentiated AL, or retention of the ETP-ALL phenotype. ETP-ALL relapse requires careful clinical and laboratory diagnosis. Treatment decisions should rely mainly on initial examination data, taking into account both immunophenotypic and molecular/genetic characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunophenotypic but Not Genetic Changes Reclassify the Majority of Relapsed/Refractory Pediatric Cases of Early T-Cell Precursor Acute Lymphoblastic Leukemia

Demina,

Dagestani,

Borkovskaia

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Early T-cell precursor leukemia: questions of diagnosis, treatment and description of own clinical case

Korkina

Валиев

Киргизов

et al. 2023

Ross. ž. det. gematol. onkol.

View full text Add to dashboard Cite

Early T-cell precursor leukemia (early T-cell precursor, ETP-ALL) is a new subvariant of acute lymphoblastic leukemia (ALL). Tumor blasts have a unique phenotype, including signs of both stem and myeloid cells. This fact significantly complicates differential diagnosis. Cytogenetic and molecular biological features of cells in ETP-ALL are the most important diagnostic criteria. Nowadays the leading scientific international groups of pediatric leukemia conduct researches to develop new treatment protocols for ETP-ALL or to optimize existing chemotherapy regimens by including targeted drugs (bortezomib, ruxolitinib, venetoclax). Currently, hematopoietic stem cell transplantation is a mandatory option in the treatment of ETP-ALL. Targeted drugs and CAR-T-cell (chimeric antigen receptor of T-cells) therapy are the most perspective ways of posable treatment. In this article there are summarized data on diagnosis and therapy and a description of a successful treatment of a patient with ETP-ALL.

show abstract

Flow cytometry in acute leukemia diagnostics. Guidelines of Russian-Belarusian multicenter group for pediatric leukemia studies

Popov

Verzhbitskaya

Movchan

et al. 2023

Voprosy gematologii/onkologii i immunopatologii v pediatrii

Self Cite

View full text Add to dashboard Cite

Flow cytometry is one of the key technologies for acute leukemia (AL) diagnostics. Nevertheless, lack of technological standards hampers implementation of immunophenotyping data in treatment protocols. Earlier our group published the acute lymphoblastic leukemia diagnostic standards. In this paper, we present the updated guidelines for initial immunophenotyping of ALs. This wellharmonized approach includes recommendations for monoclonal antibodies choice, sample preparation, cytometer setup, data analysis and interpretation as well as for the report writing. These guidelines allows application of diagnostic flow cytometric studies in all types of AL.

show abstract

Immunophenotypic characteristics of early T-cell precursor acute lymphoblastic leukemia

Cited by 3 publications

References 24 publications

Immunophenotypic but Not Genetic Changes Reclassify the Majority of Relapsed/Refractory Pediatric Cases of Early T-Cell Precursor Acute Lymphoblastic Leukemia

Immunophenotypic but Not Genetic Changes Reclassify the Majority of Relapsed/Refractory Pediatric Cases of Early T-Cell Precursor Acute Lymphoblastic Leukemia

Early T-cell precursor leukemia: questions of diagnosis, treatment and description of own clinical case

Flow cytometry in acute leukemia diagnostics. Guidelines of Russian-Belarusian multicenter group for pediatric leukemia studies

Contact Info

Product

Resources

About